Overview

A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

Status:
Completed
Trial end date:
2015-10-19
Target enrollment:
Participant gender:
Summary
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice
Phase:
Phase 4
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Loteprednol Etabonate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate